
SelectX Pharmaceuticals Inc.: Boston-based biopharmaceutical firm developing advanced aminoglycoside therapeutics for unmet medical needs.
SelectX Pharmaceuticals Inc. is a Boston-based biopharmaceutical company focused on the discovery and development of advanced aminoglycoside therapeutics to address unmet medical needs. Their flagship product, SXP2523, is a next-generation aminoglycoside antibiotic targeting drug-resistant gram-negative hospital-acquired infections. The company is also working on an inhaled aminoglycoside antibiotic.
SelectX Pharmaceuticals has made significant strides in developing novel treatments for challenging infections, positioning itself as a key player in the biopharmaceutical industry. Their innovative approach to aminoglycoside therapeutics has garnered attention for its potential to combat drug-resistant bacteria, addressing a critical gap in current medical treatments.

X-Biotix Therapeutics

Nexcida Therapeutics

Taxis Pharmaceuticals
taxispharma.com

Recida Therapeutics

Venatorx Pharmaceuticals
venatorx.com

Spero Therapeutics

Xoc Pharmaceuticals

Summit Therapeutics
summittxinc.com

Atterx BioTherapeutics
atterx.com

Cardeas Pharma

X4 Pharmaceuticals
x4pharma.com

Synereca Pharmaceuticals

Endolytix

Bioxiness Pharmaceuticals

Revagenix
revagenix.com
Companies similar to SelectX Pharmaceuticals include X-Biotix Therapeutics, Nexcida Therapeutics, Taxis Pharmaceuticals and Recida Therapeutics.
SelectX Pharmaceuticals was founded in 2002.
SelectX Pharmaceuticals' headquarters is located in Boston, MA, US.
SelectX Pharmaceuticals' most recent funding round was for $8M (USD) in January 2004.
As of Jan 23, 2004, SelectX Pharmaceuticals has raised a total of $8M (USD).
SelectX Pharmaceuticals has 30 employees as of Feb 4, 2024.